ClinicalTrials.gg
RecruitingNCT07455578Updated Jun 1, 2026

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

A Phase 1 interventional study of S-4321 in Autoimmune Diseases, Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA), sponsored by Seismic Therapeutic AU Pty Ltd. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Primary conditionArthritis, RheumatoidRegistry: Autoimmune DiseasesReclassifiedWhy we changed it
Registry
Autoimmune Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis, Rheumatoid
Why
  1. The study's listed conditions name Arthritis, Rheumatoid, a narrower term within Autoimmune Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Seismic Therapeutic AU Pty Ltd · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Arthritis, Rheumatoid with a site in Australia — 16 open to participants now, 21 under way, 3 of them phase 3. Arthritis, Rheumatoid · Australia.

Planned enrollment
133rd of 140
24 · median 469
Started
2026
with 8 others
Phase 1
21 of 154
12 open now
Primary completion
2027-09
later than 6 of 20 live
Registered
151st of 154
by date

Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, this one is the 133rd largest by planned enrollment of the 140 interventional ones that give a count, is one of 9 that started in 2026, is one of 21 in phase 1, reaches primary completion later than 6 of the 20 other live ones, and was the 151st registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

16 of the 154 studies in Arthritis, Rheumatoid with a site in Australia are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Arthritis, Rheumatoid with a site in Australia, or all of them as a file.
02

Study summary

This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in adults with autoimmune or immune-mediated disease including rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), cutaneous lupus erythematosus (CLE) with or without systemic manifestations, or atopic dermatitis (AD).

03

Conditions studied

  • Autoimmune Diseases
  • Rheumatoid Arthritis (RA)
  • Psoriatic Arthritis (PsA)
  • Psoriasis (PsO)
  • Cutaneous Lupus Erythematosus (CLE)
  • Atopic Dermatitis (AD)

Keywords

  • Autoimmune
  • Immune-mediated
  • S-4321
  • Seismic Therapeutic
  • Rheumatoid Arthritis
  • Atopic Dermatitis (AD)
  • Psoriasis (PsO)
  • Psoriatic Arthritis (PsA)
  • Cutaneous Lupus Erythematosus (CLE)
  • Cutaneous Lupus
04

In context

Arthritis, Rheumatoid Reclassified

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

This study's planned enrollment of 24 is below the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.

Browse Arthritis, Rheumatoid studies →

Lead sponsor

Seismic Therapeutic AU Pty Ltd is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Compared within Arthritis, Rheumatoid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autoimmune Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

All Participants Major Inclusion Criteria:

  1. Adult males and females, 18 to 75 years of age (inclusive)
  2. (BMI) ≥18.0 and \<40.0 kg/m2 with a minimum body weight of 45 kg
  3. Use of adequate for both males and females. Female volunteers must be of nonchildbearing potential or if of , must have a negative pregnancy test.

All Participants Major Exclusion Criteria:

  1. Have received a agonist, immune checkpoint agonist, immune checkpoint inhibitor, anti-CD19 or anti-CD20 agents, cell therapy, B cell modulating agents, alkylating agents, or any other immune cell depleting therapy.
  2. Have received azathioprine, cyclosporine, mycophenolate mofetil, or tacrolimus within 4 weeks
  3. Unable or unwilling to discontinue a prohibited medication
  4. Presence of
  5. Current infection or history of severe infection
  6. Any history of malignant disease, with some exceptions

Major inclusion/exclusion for each or immune-mediated disease:

For RA:

  1. Confirmed diagnosis of moderate to severe active RA by the American College of Rheumatology (ACR) 2010/European League Against Rheumatism (EULAR) criteria for at least 3 months prior to the Screening 1 visit, and:

    1. ≥6 swollen joint count based on 66 joint count
    2. ≥6 tender joint count based on 68 joint count
    3. Seropositive for RF and/or ACPA
    4. Elevated hsCRP ≥1.2 times greater than the
    5. Does not have Class IV RA according to ACR revised criteria
  2. Inadequate response to, or loss of response, or intolerance to:

    1. >1 conventional synthetic DMARD after 3 months of therapy OR
    2. >1 biologic DMARD/targeted synthetic DMARD after 3 months of therapy
    3. Has not failed 3 or more bDMARDs and/or tsDMARDs

For PsA:

  1. Confirmed diagnosis of adult-onset PsA classified by the Classification Criteria for Psoriatic Arthritis (CASPAR) for at least 3 months prior to the Screening 1 visit, with all of the following:

    1. Active PsO defined by at least 1 psoriasis lesion
    2. Active disease defined by >3 swollen joints and >3 tender joints using the 76/78 swollen and tender joint count
  2. Received standard doses of NSAIDs for >4 weeks or csDMARDs for >3 months and has been on a stable dose for >8 weeks, or participant has intolerance to NSAIDs or DMARDs
  3. Participants may be TNF inhibitor therapy naïve or may have received 1 prior TNF inhibitor
  4. Has not had inadequate response or intolerance to 2 or more bDMARDs or csDMARDs

For PsO:

  1. Confirmed diagnosis of moderate to severe plaque PsO for at least 6 months, with all of the following:

    1. Psoriasis Area and Severity Index (PASI) >12 points
    2. Static Physician's Global Assessment (sPGA) >3 points
    3. Body surface area (BSA) of PsO involvement >10%
  2. Cannot have a clinically significant flare within 12 weeks
  3. Does not have history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis
  4. Has not had inadequate response to more than 2 prior bDMARDs

For CLE (with or without systemic manifestations):

  1. confirmed diagnosis of CLE with or without systemic manifestations for at least 6 months
  2. Has active skin manifestations as measured by CLASI-A >10 or CLASI-A >8, if there is no alopecia or mucous membrane lesions
  3. Participant must have an active CLE lesion despite an adequate trial of antimalarial treatment for at least 6 months.
  4. Cannot have active lupus nephritis or moderate-to-severe or chronic kidney disease with \<45 mL/min/1.73m2
  5. Cannot have active neuropsychiatric SLE

For AD:

  1. Confirmed diagnosis of AD as defined by the American Academy of Dermatology: Guidelines of Care for the Management of Atopic Dermatitis for at least 12 months

    1. Eczema Area and Severity Index (EASI) >16
    2. Validated Investigator Global Assessment (vIGA-AD) >3
    3. BSA of AD involvement >10%
    4. PP-NRS) >4 (average of daily scores) during the 7 days prior to dosing
  2. Inadequate response to existing topical medications within 6 months or has a history of intolerance to topical therapy as defined by at least 1 of the following:

    1. Inability to achieve good disease control after use TCS for at least 4 weeks
    2. Documented history of clinically significant AEs with the use of TCS
    3. Failed systemic therapies intended to treat AD within 6 months

Additional inclusion/exclusion criteria will apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    S-4321

    SC Dose of S-4321

    Drug: S-4321

Interventions

  • DrugS-4321

    Multiple doses of S-4321 via subcutaneous administration

07

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Through Week 31

  2. Incidence of serious adverse events (SAEs)

    Time frame: Through Week 31

Secondary outcomes

  1. Serum concentration of S-4321

    Time frame: Through Week 28

  2. Change from baseline in percent Receptor Occupancy (RO)

    Time frame: Through Week 28

  3. Change from baseline of soluble PD-1 (sPD-1)

    Time frame: Through Week 28

  4. Incidence of anti-drug antibodies (ADAs)

    Time frame: Through Week 28

08

Study locations

2 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: No — IPD sharing plan is not yet developed. Sponsor will consider data sharing at a later date.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Sep 2027, 15 months later.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 15 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Mar 6, 2026
StartEst.
Jun 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07455578
Lead sponsor
Seismic Therapeutic AU Pty Ltd
Collaborators
Avance Clinical Pty Ltd.
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Jun 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Seismic Contact
Contact
clinical@seismictx.com
1800 244 475
Jennifer Martin, MD
principal investigator · Novatrials

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion